SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool is a research paper published in Journal of Geriatric Oncology (2021). On theSindex it has a DataRank of 0.736. It has been cited 24 times, with 19 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.483
From this paper's citation signal
Citation Network Contribution
0.253
From 14 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 19 citers.
National Institutes of Health
Grant: U10CA180819
National Institutes of Health
Grant: U10CA180820
National Institutes of Health
Grant: U10CA180821
National Institutes of Health
Grant: U10CA180888
NCI NIH HHS
Grant: UG1 CA233230
NCI NIH HHS
Grant: UG1 CA233373
National Institutes of Health
Grant: 3U10CA180888-03S1
SWOG Network Group Operations Center of the NCTN
National Institutes of Health
Grant: 2U10CA180819-06
SWOG Statistics and Data Management Center
National Institutes of Health
Grant: 3U10CA180821-02S2
Alliance for Clinical Trials in Oncology Operations Center
Bristol-Myers Squibb
Celgene
FWCI
2.44
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMA-CNS trial
Additional file 1 of Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMA-CNS trial